Adalimumab (Humira): Uses, MOA, Safety & Key Facts

What is adalimumab?

Adalimumab is an active ingredient used in medicines for inflammatory and immune-mediated conditions. It is available under several brand names, including Humira, Hyrimoz, Amjevita, and Cyltezo in the United States.

Because brand names and approved uses can vary by country and product, it is important to check the exact medicine label and official leaflet for the product you have been prescribed.

How adalimumab works

Adalimumab binds to TNF and neutralizes its biological function by blocking its interaction with TNF receptors on the cell surface.

It also modulates biological responses linked to TNF, including changes in adhesion molecules involved in leukocyte migration.

What adalimumab is used for

Adalimumab is used for a range of conditions, including:

• Rheumatoid arthritis
• Juvenile idiopathic arthritis
• Ankylosing spondylitis
• Axial spondyloarthritis
• Psoriatic arthritis
• Psoriasis
• Hidradenitis suppurativa
• Crohn’s disease
• Ulcerative colitis
• Uveitis

Some uses apply to adults only, while others apply to children or adolescents. The exact approved use depends on the specific product and age group.

Examples of approved uses listed in the source content

• Rheumatoid arthritis in adults, including use with methotrexate in some situations.
• Juvenile idiopathic arthritis, including polyarticular disease and arthritis associated with enthesitis.
• Severe active ankylosing spondylitis and severe axial spondyloarthritis with objective signs of inflammation.
• Active psoriatic arthritis in adults.
• Moderate to severe chronic plaque psoriasis in adults, and severe chronic plaque psoriasis in children and adolescents from age 4 in certain cases.
• Moderate to severe hidradenitis suppurativa in adults and some adolescents.
• Crohn’s disease in adults and children in specific situations.
• Ulcerative colitis in adults in specific situations.
• Non-infectious uveitis, including some pediatric uveitis indications.

Adalimumab dosage and administration

Adalimumab is given by subcutaneous injection.

The source content includes different dosing schedules depending on the condition, age, and body weight. Because these schedules vary widely, the exact dose should be checked in the official product leaflet and confirmed by a healthcare professional.

Contraindications

The source content lists the following contraindications:

• Hypersensitivity to adalimumab
• Active tuberculosis
• Other serious infections such as sepsis and opportunistic infections
• Moderate to severe heart failure

Warnings and precautions

Important cautions mentioned in the source content include:

• Renal insufficiency and hepatic insufficiency
• Neurological effects
• Possible demyelinating disorders affecting the peripheral or central nervous system
• Allergic reactions
• Malignant neoplastic diseases and lymphoproliferative disorders
• Hematologic reactions
• Heart failure, including caution in mild heart failure
• Autoimmune processes and antibody formation
• Use with other biologic agents such as abatacept or anakinra is not recommended in the source content
• Infection monitoring, including tuberculosis screening before and during treatment
• Hepatitis B reactivation risk in chronic carriers

The source content also notes that treatment should not be started in the presence of active infections until they are controlled.

Infections and vaccination

Serious infections have been reported with adalimumab, including bacterial, mycobacterial, fungal, parasitic, viral, and other opportunistic infections.

In pediatric patients, vaccination schedules should be updated before treatment begins, and live vaccines should not be given during treatment.

Pregnancy and breastfeeding

The source content says there is no experience in pregnant women and that adalimumab is not recommended in pregnancy because it may affect the newborn’s immune response.

For breastfeeding, the source content states that it is not known whether adalimumab passes into breast milk or is absorbed after ingestion, and it advises not breastfeeding for at least five months after the last treatment.

These points should be reviewed with a clinician using the official product information, since recommendations can depend on the individual situation and the specific medicine.

Effects on driving and using machines

The source content says the effect on driving ability is small, but dizziness, vertigo, impaired vision, and fatigue may occur.

Possible adverse reactions

The source content lists the following adverse reactions and side effects:

• Respiratory tract infections, including upper and lower respiratory tract infections, pneumonia, sinusitis, pharyngitis, nasopharyngitis, and herpesvirus pneumonia
• Leukopenia, including neutropenia and agranulocytosis
• Anemia
• Increased lipids
• Headache
• Abdominal pain, nausea, and vomiting
• Increased liver enzymes
• Rash, including exfoliative rash
• Musculoskeletal pain
• Injection-site reactions, including redness

Key points to verify with the official leaflet

If you are reading about adalimumab for the first time, these are the most useful details to confirm with a doctor, pharmacist, or official leaflet:

• The exact brand and formulation
• The approved use for your age group
• The correct injection schedule
• Whether any other medicines are being used at the same time
• Any infection screening or vaccination steps needed before treatment

Safety reminder

FAQ

Sources and reference suggestions

The following resources were included in the original content and are useful for verification:

• FDA Medication Guide database
• UNII: FYS6T7F842
• ChemIDplus
• DrugPortal
• NCI Thesaurus: C65216